Orbis Allan Gray LTD Crispr Therapeutics Ag Transaction History
Orbis Allan Gray LTD
- $13.9 Billion
- Q1 2025
A detailed history of Orbis Allan Gray LTD transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Orbis Allan Gray LTD holds 1,562,932 shares of CRSP stock, worth $59.5 Million. This represents 0.38% of its overall portfolio holdings.
Number of Shares
1,562,932
Previous 1,476,119
5.88%
Holding current value
$59.5 Million
Previous $58.1 Million
8.46%
% of portfolio
0.38%
Previous 0.39%
Shares
2 transactions
Others Institutions Holding CRSP
# of Institutions
479Shares Held
64.2MCall Options Held
2.15MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$387 Million3.73% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$231 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$144 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$106 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.54MShares$96.6 Million0.06% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $2.97B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....